Top scientists have said that the EU’s Clinical Trial Directive is making medicine more expensive and research anti-competitive, while the long delays between trial and prescription are causing patients to "suffer".
"The Clinical Trials Directive was put forward in the spirit of harmonisation but was, in fact, a mechanism to make trials so horrendously expensive that only Big Pharma could afford to get their products registered," Professor Dalgleish and Professor Lewis wrote in BrexitCentral on Sunday.
